Press releases
* (R) = Regulatory press releases
Aug 27, 2024
(R) Cantargia reports timelines for nadunolimab clinical trials in leukemia and triple negative breast cancer
Aug 9, 2024
(R) Cantargia reports progress and strong biomarker data from phase I clinical trial with CAN10
Jul 22, 2024
(R) Cantargia reports organisational change
Jun 11, 2024
(R) Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer
Jun 1, 2024
Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy
May 23, 2024
(R) Cantargia presents new positive clinical data on nadunolimab counteracting chemotherapy induced neuropathy
May 23, 2024
